Recently, Spectrum Pharmaceuticals announced that it has met with the FDA regarding it’s supplemental New Drug Application (sNDA) for FUSILEV® (levoleucovorin) for injection for the treatment of patients with advanced metastatic colorectal cancer. The company is expected to to submit in the third quarter of 2010. The FDA did not request any additional efficacy studies. Hope the FDA will approve the drug for advanced metastatic colorectal cancer...
Ref : http://investor.spectrumpharm.com/releasedetail.cfm?ReleaseID=439605
